[{"arm_notes": "", "treatment_id": null, "treatment_name": "Drug : Treatment Group: IP (Ifenprodil) plus Standard of Care (SOC) (N=20) Control Group: Standard of Care (SOC) (N=20) TREATMENT: Test Product: Ifenprodil; 20 mg TID for up to 4 weeks; in conjunction with SOC Duration of patient participation: Up to 5 weeks The chemical name of Ifenprodil is (1RS;2SR)-4-[2-(4-Benzylpiperidin-1-yl)-1-hydroxypropyl] phenol hemi-(2R;3R)-tartrate. The drug is more commonly referred to as ifenprodil. Ifenprodil will be provided as white; round; biconvex; film-coated tablets containing 20 mg of the active ingredient. Treatment Administration and Schedule Tablets will be taken by mouth TID in the in the morning (AM; upon rising); in the afternoon (PM; 6-10 hours following first dose); and evening (PM; 6-10 hours before the next day\u2019s anticipated first dose).Best efforts should be made to keep the three doses approximately 8 hours apart. The length of dosing for the study is up to 4 weeks.The first dose of study medication will be taken on day 1 at the first visit; following randomization.In cases where the patient is unable to swallow tablets the use of a nasogastric/stomach tube is permitted. Crushing and administration of tablets should follow local practices/SOPs. Study drug administration should continue until the end of week 4; or hospital discharge; whichever comes first.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 623, "treatment_name": "Ifenprodil", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]